AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). | The ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Leerink, however, has questioned the company’s direction. In a note to clients sent out Jan. 8, the analysts said they ...

Menlo Ventures has made a $16 million bet that the “ baby KJ ” custom CRISPR therapy success story is repeatable. The funding ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...